Testosterone Replacement Therapy for Women: What the Research Says

Testosterone Is Not Just a Male Hormone

Women produce testosterone in the ovaries and adrenal glands throughout their lives. In premenopausal women, testosterone levels are typically 15-70 ng/dL — roughly 10-15x lower than in men, but biologically significant. Testosterone contributes to libido, mood, energy, bone density, muscle maintenance, and cognitive function in women, just as it does in men.

What most women (and many physicians) don't realize: testosterone declines with age in women just as it does in men. Levels at 40 are typically half of what they were at 20. Menopause accelerates this decline. After oophorectomy (ovary removal), testosterone drops by approximately 50% virtually overnight.

Despite this physiology, testosterone therapy for women remains significantly underutilized, under-researched relative to male TRT, and underappreciated as a treatment option. This is changing — but slowly.

Symptoms of Low Testosterone in Women

The overlap with other hormonal conditions (low estrogen, hypothyroidism, depression) makes diagnosis challenging. Symptoms of low testosterone in women include:

Sexual function: - Reduced libido (the most consistently studied symptom) - Difficulty achieving orgasm - Reduced genital sensitivity - Decreased arousal

Energy and cognition: - Persistent fatigue not explained by sleep or lifestyle - Difficulty concentrating, mental fog - Reduced motivation and drive - Loss of competitive edge or ambition

Body composition: - Loss of muscle mass and strength - Increased fat accumulation despite no dietary changes - Reduced exercise tolerance

Mood: - Depression, particularly with low affect and blunted emotion - Anxiety - Reduced sense of wellbeing

Many women with these symptoms are told their labs are "normal" because physicians only checked estrogen and TSH. Without testosterone testing, the diagnosis is missed.

What the Evidence Shows

### Libido and Sexual Function — Strongest Evidence

The most robust evidence for testosterone therapy in women is for hypoactive sexual desire disorder (HSDD) — clinically significant low libido that causes distress. Multiple randomized controlled trials, primarily in postmenopausal women, show meaningful improvements in:

• Frequency of satisfying sexual events
• Sexual desire
• Arousal and pleasure
• Reduced distress about sexual function

The Global Consensus Position Statement on the Use of Testosterone Therapy for Women (2019), endorsed by multiple major endocrinology and gynecology societies, concluded that testosterone therapy is appropriate for postmenopausal women with HSDD, with a reasonable evidence base and acceptable safety profile when used physiologically (targeting testosterone levels in the upper normal premenopausal range).

### Mood and Energy

Evidence is less consistent but positive overall. Studies show improvements in wellbeing, energy, mood, and quality of life in women with low testosterone who receive replacement. The effect is most pronounced in women with documented low levels rather than supplementation on top of normal levels.

### Body Composition

Testosterone promotes muscle protein synthesis and fat oxidation in women just as in men, though less dramatically. Studies in postmenopausal women show testosterone therapy preserves lean mass and reduces fat mass when combined with exercise. The effect on bone density is also documented.

### Cognitive Function

Emerging evidence suggests testosterone may support cognitive function in women, particularly verbal memory and spatial ability. Trials are ongoing, but preliminary data is encouraging, especially in the context of menopause-related cognitive changes.

Who Should Consider Testosterone Therapy

Postmenopausal women with HSDD and/or general symptoms of androgen deficiency are the best-established candidates. The evidence base is strongest here.

Surgically menopausal women (post-oophorectomy) have an abrupt, dramatic drop in testosterone and are high-priority candidates regardless of age.

Premenopausal women with documented low testosterone and consistent symptoms may benefit, though evidence is less extensive. Comprehensive evaluation to rule out other causes is essential first.

Women on oral contraceptives often have dramatically suppressed testosterone (OCPs increase SHBG, reducing free testosterone). Switching to a non-hormonal or non-oral contraceptive method may normalize levels without requiring exogenous testosterone.

How Female TRT Works

Dose: Women require much lower doses than men. Typical therapeutic doses target serum testosterone in the upper normal premenopausal range — roughly 50-100 ng/dL total testosterone.

Forms: - Transdermal cream or gel: Applied to inner arm, inner thigh, or vaginal area. Available via compounding pharmacy. Most commonly used. - Pellets: Implanted subcutaneously. Long-acting (3-4 months) but dose adjustment is difficult if issues arise. - Injections: Less commonly used for women due to difficulty titrating low doses.

No FDA-approved product specifically for women currently exists in the United States — a significant gap that reflects the underinvestment in women's hormonal health research. Women are treated with compounded preparations or off-label use of male products at much lower doses.

Safety Considerations

Androgenic side effects: The most common concern. Dose-dependent. At physiological replacement doses targeting the upper normal female range, side effects are uncommon. With supraphysiologic doses, acne, increased body/facial hair, clitoral enlargement, and voice changes can occur. These are the key reasons dose precision matters.

Cardiovascular: No evidence of increased cardiovascular risk at physiological doses. Evidence on lipid effects is mixed but generally neutral at appropriate doses.

Breast cancer: No established increase in breast cancer risk from testosterone therapy. Some evidence suggests possible protective effects, though data is insufficient to draw firm conclusions.

Monitoring: Total testosterone, free testosterone, SHBG, estradiol, and complete metabolic panel every 3-6 months during titration.

What to Expect From Treatment

Women who respond to testosterone therapy (most do, when appropriate candidates are selected) typically report:

• Improved libido within 3-6 weeks
• Better energy and mood within 4-8 weeks
• Improved body composition over 3-6 months with exercise
• Improved sense of wellbeing — often described as "feeling like myself again"

The conversation about women's hormonal health is finally expanding beyond estrogen and progesterone. Testosterone is a critical part of the picture that deserves equal attention.

At Marrow, we evaluate testosterone as part of comprehensive hormonal assessment in women, not as an afterthought. If your symptoms suggest androgen deficiency and your providers haven't checked it — it's time to get the full picture.